These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

344 related items for PubMed ID: 18596602

  • 1. Risks and benefits of therapy with menopausal hormones versus selective estrogen-receptor modulators in peri- and postmenopausal women at increased breast cancer risk.
    Col NF, Chlebowski RT.
    Menopause; 2008; 15(4 Suppl):804-9. PubMed ID: 18596602
    [Abstract] [Full Text] [Related]

  • 2. Risks, benefits, and effects on quality of life of selective estrogen-receptor modulator therapy in postmenopausal women at increased risk of breast cancer.
    Ganz PA, Land SR.
    Menopause; 2008; 15(4 Suppl):797-803. PubMed ID: 18596601
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Effect of raloxifene on the incidence of invasive breast cancer in postmenopausal women with osteoporosis categorized by breast cancer risk.
    Lippman ME, Cummings SR, Disch DP, Mershon JL, Dowsett SA, Cauley JA, Martino S.
    Clin Cancer Res; 2006 Sep 01; 12(17):5242-7. PubMed ID: 16951244
    [Abstract] [Full Text] [Related]

  • 5. Chemoprevention in postmenopausal women.
    Rastogi P.
    Menopause; 2008 Sep 01; 15(4 Suppl):810-5. PubMed ID: 18596603
    [Abstract] [Full Text] [Related]

  • 6. Prophylaxis approach to a-symptomatic post-menopausal women: breast cancer.
    Aguas F, Martins A, Gomes TP, de Sousa M, Silva DP, Portuguese Menopause Society and Portuguese Gynaecology Society.
    Maturitas; 2005 Nov 15; 52 Suppl 1():S23-31. PubMed ID: 16126355
    [Abstract] [Full Text] [Related]

  • 7. Standard and low-dose hormone therapy for postmenopausal women--focus on the breast.
    Wang PH, Horng HC, Cheng MH, Chao HT, Chao KC.
    Taiwan J Obstet Gynecol; 2007 Jun 15; 46(2):127-34. PubMed ID: 17638620
    [Abstract] [Full Text] [Related]

  • 8. Raloxifene use in clinical practice: efficacy and safety.
    Goldstein SR, Duvernoy CS, Calaf J, Adachi JD, Mershon JL, Dowsett SA, Agnusdei D, Stuenkel CA.
    Menopause; 2009 Jun 15; 16(2):413-21. PubMed ID: 19092711
    [Abstract] [Full Text] [Related]

  • 9. Breast cancer risk reduction: what do we know and where should we go?
    Prout MN.
    Medscape Womens Health; 2000 Jun 15; 5(5):E4. PubMed ID: 11113777
    [Abstract] [Full Text] [Related]

  • 10. The STAR trial: evidence for raloxifene as a breast cancer risk reduction agent for postmenopausal women.
    Bevers TB.
    J Natl Compr Canc Netw; 2007 Sep 15; 5(8):719-24. PubMed ID: 17927929
    [Abstract] [Full Text] [Related]

  • 11. Hormone replacement therapy in women with a history of breast cancer.
    Ylikorkala O, Metsä-Heikkilä M.
    Gynecol Endocrinol; 2002 Dec 15; 16(6):469-78. PubMed ID: 12626034
    [Abstract] [Full Text] [Related]

  • 12. The addition of hormone therapy to tamoxifen does not prevent hot flashes in women at high risk for developing breast cancer.
    Osborne CR, Duncan A, Sedlacek S, Paul D, Holmes F, Vukelja S, Kasper M, Wilks S, Schneider A, McGee R, Meyer WG, O'Shaughnessy JA.
    Breast Cancer Res Treat; 2009 Aug 15; 116(3):521-7. PubMed ID: 19139988
    [Abstract] [Full Text] [Related]

  • 13. Rationale for using raloxifene to prevent both osteoporosis and breast cancer in postmenopausal women.
    Lee WL, Chao HT, Cheng MH, Wang PH.
    Maturitas; 2008 Jun 20; 60(2):92-107. PubMed ID: 18534794
    [Abstract] [Full Text] [Related]

  • 14. Epidemiology, genetics, and risk evaluation of postmenopausal women at risk of breast cancer.
    Vogel VG.
    Menopause; 2008 Jun 20; 15(4 Suppl):782-9. PubMed ID: 18596599
    [Abstract] [Full Text] [Related]

  • 15. Selective modulation of postmenopausal women: cutting the Gordian knot of hormone replacement therapy with breast carcinoma.
    Diamanti-Kandarakis E, Sykiotis GP, Papavassiliou AG.
    Cancer; 2003 Jan 01; 97(1):12-20. PubMed ID: 12491500
    [Abstract] [Full Text] [Related]

  • 16. Postmenopausal hormone therapy before and after breast cancer: clinical experiences.
    Bundred NJ, Turner LE.
    Maturitas; 2004 Sep 24; 49(1):S22-31. PubMed ID: 15351104
    [Abstract] [Full Text] [Related]

  • 17. Sex hormones, risk factors, and risk of estrogen receptor-positive breast cancer in older women: a long-term prospective study.
    Cummings SR, Lee JS, Lui LY, Stone K, Ljung BM, Cauleys JA.
    Cancer Epidemiol Biomarkers Prev; 2005 May 24; 14(5):1047-51. PubMed ID: 15894651
    [Abstract] [Full Text] [Related]

  • 18. Recent results from clinical trials using SERMs to reduce the risk of breast cancer.
    Vogel VG.
    Ann N Y Acad Sci; 2006 Nov 24; 1089():127-42. PubMed ID: 17261762
    [Abstract] [Full Text] [Related]

  • 19. Managing menopause.
    Cutson TM, Meuleman E.
    Am Fam Physician; 2000 Mar 01; 61(5):1391-400, 1405-6. PubMed ID: 10735345
    [Abstract] [Full Text] [Related]

  • 20. Reducing the risk of breast cancer with tamoxifen in women at increased risk.
    Vogel VG.
    J Clin Oncol; 2001 Sep 15; 19(18 Suppl):87S-92S. PubMed ID: 11560980
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.